Perspective Therapeutics, Inc. (AMEX: CATX) Stock Competitors & Peer Comparison
See CATX's competitors and their performance on the AMEX and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CATX and its AMEX peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CATX | $0.84 | +6.54% | 95.9M | -0.63 | -$1.33 | N/A |
| ABT | $109.93 | -3.23% | 190.3B | 21.10 | $5.21 | +2.28% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| MDT | $101.80 | -2.90% | 130.2B | 18.41 | $5.53 | +2.81% |
| SYK | $325.87 | -2.75% | 124.1B | 24.34 | $13.39 | +1.09% |
| BSX | $42.75 | -4.23% | 62B | 13.79 | $3.10 | N/A |
| EW | $102.14 | +1.31% | 58.9B | 37.82 | $2.70 | N/A |
| GEHC | $82.38 | -1.64% | 37.2B | 16.81 | $4.90 | +0.18% |
| PHG | $30.35 | -0.52% | 29.7B | 17.34 | $1.75 | +3.27% |
| DXCM | $79.41 | -5.98% | 29.6B | 31.14 | $2.55 | N/A |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
CATX vs ABT Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, ABT has a market cap of 190.3B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while ABT trades at $109.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas ABT's P/E ratio is 21.10. In terms of profitability, CATX's ROE is -0.42%, compared to ABT's ROE of +0.09%. Regarding short-term risk, CATX is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for CATX.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
CATX vs BSX-PA Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, CATX's ROE is -0.42%, compared to BSX-PA's ROE of +0.14%. Regarding short-term risk, CATX is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for CATX.Check BSX-PA's competition here
Medtronic Plc (NYSE: MDT)
CATX vs MDT Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, MDT has a market cap of 130.2B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while MDT trades at $101.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas MDT's P/E ratio is 18.41. In terms of profitability, CATX's ROE is -0.42%, compared to MDT's ROE of +0.11%. Regarding short-term risk, CATX is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for CATX.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
CATX vs SYK Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, SYK has a market cap of 124.1B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while SYK trades at $325.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas SYK's P/E ratio is 24.34. In terms of profitability, CATX's ROE is -0.42%, compared to SYK's ROE of +0.16%. Regarding short-term risk, CATX is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for CATX.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
CATX vs BSX Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, BSX has a market cap of 62B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while BSX trades at $42.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas BSX's P/E ratio is 13.79. In terms of profitability, CATX's ROE is -0.42%, compared to BSX's ROE of +0.14%. Regarding short-term risk, CATX is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for CATX.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
CATX vs EW Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, EW has a market cap of 58.9B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while EW trades at $102.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas EW's P/E ratio is 37.82. In terms of profitability, CATX's ROE is -0.42%, compared to EW's ROE of +0.10%. Regarding short-term risk, CATX is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for CATX.Check EW's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
CATX vs GEHC Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, GEHC has a market cap of 37.2B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while GEHC trades at $82.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas GEHC's P/E ratio is 16.81. In terms of profitability, CATX's ROE is -0.42%, compared to GEHC's ROE of +0.16%. Regarding short-term risk, CATX is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for CATX.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
CATX vs PHG Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, PHG has a market cap of 29.7B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while PHG trades at $30.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas PHG's P/E ratio is 17.34. In terms of profitability, CATX's ROE is -0.42%, compared to PHG's ROE of +0.08%. Regarding short-term risk, CATX is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for CATX.Check PHG's competition here
DexCom, Inc. (NASDAQ: DXCM)
CATX vs DXCM Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, DXCM has a market cap of 29.6B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while DXCM trades at $79.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas DXCM's P/E ratio is 31.14. In terms of profitability, CATX's ROE is -0.42%, compared to DXCM's ROE of +0.37%. Regarding short-term risk, CATX is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for CATX.Check DXCM's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
CATX vs ZBH Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, ZBH has a market cap of 20.1B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while ZBH trades at $105.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas ZBH's P/E ratio is 12.45. In terms of profitability, CATX's ROE is -0.42%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, CATX is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for CATX.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
CATX vs ABMD Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas ABMD's P/E ratio is 65.36. In terms of profitability, CATX's ROE is -0.42%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, CATX is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for CATX.Check ABMD's competition here
Glaukos Corporation (NYSE: GKOS)
CATX vs GKOS Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, GKOS has a market cap of 13.3B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while GKOS trades at $224.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas GKOS's P/E ratio is -260.83. In terms of profitability, CATX's ROE is -0.42%, compared to GKOS's ROE of -0.25%. Regarding short-term risk, CATX is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for CATX.Check GKOS's competition here
Smith & Nephew plc (NYSE: SNN)
CATX vs SNN Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, SNN has a market cap of 13.1B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while SNN trades at $31.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas SNN's P/E ratio is 21.03. In terms of profitability, CATX's ROE is -0.42%, compared to SNN's ROE of +0.12%. Regarding short-term risk, CATX is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for CATX.Check SNN's competition here
Penumbra, Inc. (NYSE: PEN)
CATX vs PEN Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while PEN trades at $319.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas PEN's P/E ratio is 83.37. In terms of profitability, CATX's ROE is -0.42%, compared to PEN's ROE of +0.10%. Regarding short-term risk, CATX is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for CATX.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
CATX vs SWAV Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas SWAV's P/E ratio is 78.76. In terms of profitability, CATX's ROE is -0.42%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, CATX is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for CATX.Check SWAV's competition here
Align Technology, Inc. (NASDAQ: ALGN)
CATX vs ALGN Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, ALGN has a market cap of 11.8B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while ALGN trades at $166.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas ALGN's P/E ratio is 15.14. In terms of profitability, CATX's ROE is -0.42%, compared to ALGN's ROE of +0.12%. Regarding short-term risk, CATX is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for CATX.Check ALGN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
CATX vs BIO Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, BIO has a market cap of 10.2B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while BIO trades at $381.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas BIO's P/E ratio is 41.12. In terms of profitability, CATX's ROE is -0.42%, compared to BIO's ROE of +0.14%. Regarding short-term risk, CATX is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for CATX.Check BIO's competition here
Insulet Corp. (NASDAQ: PODD)
CATX vs PODD Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, PODD has a market cap of 10.2B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while PODD trades at $146.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas PODD's P/E ratio is 24.96. In terms of profitability, CATX's ROE is -0.42%, compared to PODD's ROE of +0.29%. Regarding short-term risk, CATX is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for CATX.Check PODD's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
CATX vs BIO-B Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, BIO-B has a market cap of 9.9B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while BIO-B trades at $374.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas BIO-B's P/E ratio is -65.97. In terms of profitability, CATX's ROE is -0.42%, compared to BIO-B's ROE of +0.14%. Regarding short-term risk, CATX is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for CATX.Check BIO-B's competition here
Globus Medical, Inc. (NYSE: GMED)
CATX vs GMED Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, GMED has a market cap of 9.5B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while GMED trades at $71.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas GMED's P/E ratio is 16.00. In terms of profitability, CATX's ROE is -0.42%, compared to GMED's ROE of +0.12%. Regarding short-term risk, CATX is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for CATX.Check GMED's competition here
Masimo Corporation (NASDAQ: MASI)
CATX vs MASI Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas MASI's P/E ratio is 44.43. In terms of profitability, CATX's ROE is -0.42%, compared to MASI's ROE of +0.09%. Regarding short-term risk, CATX is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for CATX.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
CATX vs BRKR Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, BRKR has a market cap of 9.3B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while BRKR trades at $61.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas BRKR's P/E ratio is 30.81. In terms of profitability, CATX's ROE is -0.42%, compared to BRKR's ROE of -0.05%. Regarding short-term risk, CATX is more volatile compared to BRKR. This indicates higher risk in terms of short-term price fluctuations for CATX.Check BRKR's competition here
Bruker Corporation (NASDAQ: BRKRP)
CATX vs BRKRP Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, BRKRP has a market cap of 9.3B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while BRKRP trades at $446.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas BRKRP's P/E ratio is 244.34. In terms of profitability, CATX's ROE is -0.42%, compared to BRKRP's ROE of -0.05%. Regarding short-term risk, CATX is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for CATX.Check BRKRP's competition here
Haemonetics Corporation (NYSE: HAE)
CATX vs HAE Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, HAE has a market cap of 5.5B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while HAE trades at $119.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas HAE's P/E ratio is 23.93. In terms of profitability, CATX's ROE is -0.42%, compared to HAE's ROE of +0.12%. Regarding short-term risk, CATX is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for CATX.Check HAE's competition here
LivaNova PLC (NASDAQ: LIVN)
CATX vs LIVN Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, LIVN has a market cap of 4.9B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while LIVN trades at $89.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas LIVN's P/E ratio is 21.37. In terms of profitability, CATX's ROE is -0.42%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, CATX is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for CATX.Check LIVN's competition here
Inari Medical, Inc. (NASDAQ: NARI)
CATX vs NARI Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas NARI's P/E ratio is -59.24. In terms of profitability, CATX's ROE is -0.42%, compared to NARI's ROE of -0.00%. Regarding short-term risk, CATX is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for CATX.Check NARI's competition here
Integer Holdings Corporation (NYSE: ITGR)
CATX vs ITGR Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while ITGR trades at $126.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas ITGR's P/E ratio is 19.94. In terms of profitability, CATX's ROE is -0.42%, compared to ITGR's ROE of +0.06%. Regarding short-term risk, CATX is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for CATX.Check ITGR's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
CATX vs TMDX Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, TMDX has a market cap of 3.1B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while TMDX trades at $88.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas TMDX's P/E ratio is 44.77. In terms of profitability, CATX's ROE is -0.42%, compared to TMDX's ROE of +0.28%. Regarding short-term risk, CATX is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for CATX.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
CATX vs AXGN Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, AXGN has a market cap of 3B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while AXGN trades at $50.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas AXGN's P/E ratio is 131.53. In terms of profitability, CATX's ROE is -0.42%, compared to AXGN's ROE of -0.11%. Regarding short-term risk, CATX is more volatile compared to AXGN. This indicates higher risk in terms of short-term price fluctuations for CATX.Check AXGN's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
CATX vs IRTC Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, IRTC has a market cap of 3B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while IRTC trades at $90.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas IRTC's P/E ratio is -209.53. In terms of profitability, CATX's ROE is -0.42%, compared to IRTC's ROE of -0.23%. Regarding short-term risk, CATX is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for CATX.Check IRTC's competition here
Neogen Corporation (NASDAQ: NEOG)
CATX vs NEOG Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, NEOG has a market cap of 2.6B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while NEOG trades at $11.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas NEOG's P/E ratio is 42.00. In terms of profitability, CATX's ROE is -0.42%, compared to NEOG's ROE of -0.03%. Regarding short-term risk, CATX is more volatile compared to NEOG. This indicates higher risk in terms of short-term price fluctuations for CATX.Check NEOG's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
CATX vs UFPT Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while UFPT trades at $303.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas UFPT's P/E ratio is 30.94. In terms of profitability, CATX's ROE is -0.42%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, CATX is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for CATX.Check UFPT's competition here
NuVasive, Inc. (NASDAQ: NUVA)
CATX vs NUVA Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas NUVA's P/E ratio is 75.00. In terms of profitability, CATX's ROE is -0.42%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, CATX is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for CATX.Check NUVA's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
CATX vs ESTA Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, ESTA has a market cap of 2B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while ESTA trades at $67.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas ESTA's P/E ratio is -53.24. In terms of profitability, CATX's ROE is -0.42%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, CATX is more volatile compared to ESTA. This indicates higher risk in terms of short-term price fluctuations for CATX.Check ESTA's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
CATX vs INSP Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, INSP has a market cap of 1.9B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while INSP trades at $63.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas INSP's P/E ratio is 28.18. In terms of profitability, CATX's ROE is -0.42%, compared to INSP's ROE of +0.12%. Regarding short-term risk, CATX is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for CATX.Check INSP's competition here
Butterfly Network, Inc. (NYSE: BFLY)
CATX vs BFLY Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, BFLY has a market cap of 1.7B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while BFLY trades at $6.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas BFLY's P/E ratio is -26.52. In terms of profitability, CATX's ROE is -0.42%, compared to BFLY's ROE of -0.28%. Regarding short-term risk, CATX is more volatile compared to BFLY. This indicates higher risk in terms of short-term price fluctuations for CATX.Check BFLY's competition here
Enovis Corporation (NYSE: ENOV)
CATX vs ENOV Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, ENOV has a market cap of 1.6B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while ENOV trades at $27.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas ENOV's P/E ratio is 7.77. In terms of profitability, CATX's ROE is -0.42%, compared to ENOV's ROE of -0.36%. Regarding short-term risk, CATX is more volatile compared to ENOV. This indicates higher risk in terms of short-term price fluctuations for CATX.Check ENOV's competition here
Novocure Ltd (NASDAQ: NVCR)
CATX vs NVCR Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, NVCR has a market cap of 1.6B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while NVCR trades at $13.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas NVCR's P/E ratio is -12.52. In terms of profitability, CATX's ROE is -0.42%, compared to NVCR's ROE of -0.36%. Regarding short-term risk, CATX is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for CATX.Check NVCR's competition here
CONMED Corporation (NYSE: CNMD)
CATX vs CNMD Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while CNMD trades at $51.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas CNMD's P/E ratio is 11.32. In terms of profitability, CATX's ROE is -0.42%, compared to CNMD's ROE of +0.07%. Regarding short-term risk, CATX is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for CATX.Check CNMD's competition here
Heska Corporation (NASDAQ: HSKA)
CATX vs HSKA Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas HSKA's P/E ratio is -62.49. In terms of profitability, CATX's ROE is -0.42%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, CATX is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for CATX.Check HSKA's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
CATX vs LMRI Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, LMRI has a market cap of 1.3B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while LMRI trades at $13.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas LMRI's P/E ratio is -26.07. In terms of profitability, CATX's ROE is -0.42%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, CATX is more volatile compared to LMRI. This indicates higher risk in terms of short-term price fluctuations for CATX.Check LMRI's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
CATX vs TNDM Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, TNDM has a market cap of 1.2B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while TNDM trades at $16.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas TNDM's P/E ratio is -18.18. In terms of profitability, CATX's ROE is -0.42%, compared to TNDM's ROE of -0.36%. Regarding short-term risk, CATX is more volatile compared to TNDM. This indicates higher risk in terms of short-term price fluctuations for CATX.Check TNDM's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
CATX vs PRCT Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while PRCT trades at $20.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas PRCT's P/E ratio is -10.62. In terms of profitability, CATX's ROE is -0.42%, compared to PRCT's ROE of -0.33%. Regarding short-term risk, CATX is more volatile compared to PRCT. This indicates higher risk in terms of short-term price fluctuations for CATX.Check PRCT's competition here
Avanos Medical, Inc. (NYSE: AVNS)
CATX vs AVNS Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas AVNS's P/E ratio is 27.77. In terms of profitability, CATX's ROE is -0.42%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, CATX is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for CATX.Check AVNS's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
CATX vs ATEC Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, ATEC has a market cap of 1.2B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while ATEC trades at $7.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas ATEC's P/E ratio is -13.21. In terms of profitability, CATX's ROE is -0.42%, compared to ATEC's ROE of -5.47%. Regarding short-term risk, CATX is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for CATX.Check ATEC's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
CATX vs SILK Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas SILK's P/E ratio is -18.96. In terms of profitability, CATX's ROE is -0.42%, compared to SILK's ROE of -0.35%. Regarding short-term risk, CATX is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for CATX.Check SILK's competition here
Paragon 28, Inc. (NYSE: FNA)
CATX vs FNA Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas FNA's P/E ratio is -19.83. In terms of profitability, CATX's ROE is -0.42%, compared to FNA's ROE of -0.35%. Regarding short-term risk, CATX is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for CATX.Check FNA's competition here
IRadimed Corporation (NASDAQ: IRMD)
CATX vs IRMD Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while IRMD trades at $86.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas IRMD's P/E ratio is 43.16. In terms of profitability, CATX's ROE is -0.42%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, CATX is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for CATX.Check IRMD's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
CATX vs SIBN Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, SIBN has a market cap of 1.1B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while SIBN trades at $24.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas SIBN's P/E ratio is -71.29. In terms of profitability, CATX's ROE is -0.42%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, CATX is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for CATX.Check SIBN's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
CATX vs IART Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, IART has a market cap of 1B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while IART trades at $13.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas IART's P/E ratio is 5.69. In terms of profitability, CATX's ROE is -0.42%, compared to IART's ROE of +0.01%. Regarding short-term risk, CATX is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for CATX.Check IART's competition here
CeriBell, Inc. (NASDAQ: CBLL)
CATX vs CBLL Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, CBLL has a market cap of 1B. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while CBLL trades at $26.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas CBLL's P/E ratio is -15.12. In terms of profitability, CATX's ROE is -0.42%, compared to CBLL's ROE of -0.55%. Regarding short-term risk, CATX is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for CATX.Check CBLL's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
CATX vs AHCO Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, AHCO has a market cap of 998.7M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while AHCO trades at $7.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas AHCO's P/E ratio is 14.95. In terms of profitability, CATX's ROE is -0.42%, compared to AHCO's ROE of -0.29%. Regarding short-term risk, CATX is more volatile compared to AHCO. This indicates higher risk in terms of short-term price fluctuations for CATX.Check AHCO's competition here
Artivion, Inc. (NYSE: AORT)
CATX vs AORT Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, AORT has a market cap of 985.1M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while AORT trades at $20.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas AORT's P/E ratio is 33.67. In terms of profitability, CATX's ROE is -0.42%, compared to AORT's ROE of -0.04%. Regarding short-term risk, CATX is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for CATX.Check AORT's competition here
Picard Medical, Inc. (AMEX: PMI)
CATX vs PMI Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, PMI has a market cap of 877.7M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while PMI trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas PMI's P/E ratio is -7.12. In terms of profitability, CATX's ROE is -0.42%, compared to PMI's ROE of -9.31%. Regarding short-term risk, CATX is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for CATX.Check PMI's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
CATX vs CSII Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas CSII's P/E ratio is -20.83. In terms of profitability, CATX's ROE is -0.42%, compared to CSII's ROE of -0.14%. Regarding short-term risk, CATX is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for CATX.Check CSII's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
CATX vs KIDS Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, KIDS has a market cap of 829.5M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while KIDS trades at $31.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas KIDS's P/E ratio is -23.71. In terms of profitability, CATX's ROE is -0.42%, compared to KIDS's ROE of -0.10%. Regarding short-term risk, CATX is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for CATX.Check KIDS's competition here
Varex Imaging Corporation (NASDAQ: VREX)
CATX vs VREX Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, VREX has a market cap of 783.4M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while VREX trades at $18.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas VREX's P/E ratio is 19.42. In terms of profitability, CATX's ROE is -0.42%, compared to VREX's ROE of +0.05%. Regarding short-term risk, CATX is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for CATX.Check VREX's competition here
InMode Ltd. (NASDAQ: INMD)
CATX vs INMD Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, INMD has a market cap of 767.6M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while INMD trades at $13.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas INMD's P/E ratio is 9.26. In terms of profitability, CATX's ROE is -0.42%, compared to INMD's ROE of +0.12%. Regarding short-term risk, CATX is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for CATX.Check INMD's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
CATX vs CTKB Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, CTKB has a market cap of 760.4M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while CTKB trades at $5.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas CTKB's P/E ratio is -30.99. In terms of profitability, CATX's ROE is -0.42%, compared to CTKB's ROE of -0.25%. Regarding short-term risk, CATX is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for CATX.Check CTKB's competition here
Bioventus Inc. (NASDAQ: BVS)
CATX vs BVS Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, BVS has a market cap of 725.1M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while BVS trades at $10.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas BVS's P/E ratio is 13.93. In terms of profitability, CATX's ROE is -0.42%, compared to BVS's ROE of +0.27%. Regarding short-term risk, CATX is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for CATX.Check BVS's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
CATX vs BBNX Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, BBNX has a market cap of 706.8M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while BBNX trades at $15.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas BBNX's P/E ratio is -8.54. In terms of profitability, CATX's ROE is -0.42%, compared to BBNX's ROE of -0.27%. Regarding short-term risk, CATX is more volatile compared to BBNX. This indicates higher risk in terms of short-term price fluctuations for CATX.Check BBNX's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
CATX vs PACB Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, PACB has a market cap of 700.9M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while PACB trades at $2.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas PACB's P/E ratio is -5.50. In terms of profitability, CATX's ROE is -0.42%, compared to PACB's ROE of +6.04%. Regarding short-term risk, CATX is more volatile compared to PACB. This indicates higher risk in terms of short-term price fluctuations for CATX.Check PACB's competition here
Surmodics, Inc. (NASDAQ: SRDX)
CATX vs SRDX Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas SRDX's P/E ratio is -34.66. In terms of profitability, CATX's ROE is -0.42%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, CATX is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for CATX.Check SRDX's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
CATX vs TCMD Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, TCMD has a market cap of 583.1M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while TCMD trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas TCMD's P/E ratio is 24.10. In terms of profitability, CATX's ROE is -0.42%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, CATX is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for CATX.Check TCMD's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
CATX vs APEN Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas APEN's P/E ratio is -9.43. In terms of profitability, CATX's ROE is -0.42%, compared to APEN's ROE of -0.85%. Regarding short-term risk, CATX is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for CATX.Check APEN's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
CATX vs SGHT Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, SGHT has a market cap of 556.4M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while SGHT trades at $10.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas SGHT's P/E ratio is -18.04. In terms of profitability, CATX's ROE is -0.42%, compared to SGHT's ROE of -0.52%. Regarding short-term risk, CATX is more volatile compared to SGHT. This indicates higher risk in terms of short-term price fluctuations for CATX.Check SGHT's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
CATX vs AVR Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, AVR has a market cap of 554.1M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while AVR trades at $5.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas AVR's P/E ratio is -2.93. In terms of profitability, CATX's ROE is -0.42%, compared to AVR's ROE of -0.78%. Regarding short-term risk, CATX is more volatile compared to AVR. This indicates higher risk in terms of short-term price fluctuations for CATX.Check AVR's competition here
ZimVie Inc. (NASDAQ: ZIMV)
CATX vs ZIMV Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, CATX's ROE is -0.42%, compared to ZIMV's ROE of -0.07%. Regarding short-term risk, CATX is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for CATX.Check ZIMV's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
CATX vs DCTH Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, DCTH has a market cap of 518.4M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while DCTH trades at $14.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas DCTH's P/E ratio is 1494.00. In terms of profitability, CATX's ROE is -0.42%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, CATX is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for CATX.Check DCTH's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
CATX vs SENS Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, SENS has a market cap of 453.7M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while SENS trades at $8.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas SENS's P/E ratio is -3.85. In terms of profitability, CATX's ROE is -0.42%, compared to SENS's ROE of -1.66%. Regarding short-term risk, CATX is more volatile compared to SENS. This indicates higher risk in terms of short-term price fluctuations for CATX.Check SENS's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
CATX vs SSII Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, SSII has a market cap of 430M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while SSII trades at $2.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas SSII's P/E ratio is -35.75. In terms of profitability, CATX's ROE is -0.42%, compared to SSII's ROE of -0.27%. Regarding short-term risk, CATX is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for CATX.Check SSII's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
CATX vs NPCE Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, NPCE has a market cap of 428.4M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while NPCE trades at $12.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas NPCE's P/E ratio is -21.89. In terms of profitability, CATX's ROE is -0.42%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, CATX is more volatile compared to NPCE. This indicates higher risk in terms of short-term price fluctuations for CATX.Check NPCE's competition here
Avita Medical Inc. (NASDAQ: RCEL)
CATX vs RCEL Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, RCEL has a market cap of 412.4M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while RCEL trades at $16.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas RCEL's P/E ratio is -11.53. In terms of profitability, CATX's ROE is -0.42%, compared to RCEL's ROE of +1.46%. Regarding short-term risk, CATX is more volatile compared to RCEL. This indicates higher risk in terms of short-term price fluctuations for CATX.Check RCEL's competition here
Cerus Corporation (NASDAQ: CERS)
CATX vs CERS Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, CERS has a market cap of 406.9M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while CERS trades at $2.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas CERS's P/E ratio is -66.94. In terms of profitability, CATX's ROE is -0.42%, compared to CERS's ROE of -0.11%. Regarding short-term risk, CATX is more volatile compared to CERS. This indicates higher risk in terms of short-term price fluctuations for CATX.Check CERS's competition here
CapsoVision, Inc. (NASDAQ: CV)
CATX vs CV Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, CV has a market cap of 336M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while CV trades at $6.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas CV's P/E ratio is -10.02. In terms of profitability, CATX's ROE is -0.42%, compared to CV's ROE of -1.78%. Regarding short-term risk, CATX is more volatile compared to CV. This indicates higher risk in terms of short-term price fluctuations for CATX.Check CV's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
CATX vs OFIX Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, OFIX has a market cap of 317.9M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while OFIX trades at $7.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas OFIX's P/E ratio is -5.12. In terms of profitability, CATX's ROE is -0.42%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, CATX is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for CATX.Check OFIX's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
CATX vs SMLR Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas SMLR's P/E ratio is 3.92. In terms of profitability, CATX's ROE is -0.42%, compared to SMLR's ROE of +0.20%. Regarding short-term risk, CATX is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for CATX.Check SMLR's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
CATX vs CLPT Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, CLPT has a market cap of 275.5M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while CLPT trades at $8.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas CLPT's P/E ratio is -7.28. In terms of profitability, CATX's ROE is -0.42%, compared to CLPT's ROE of -1.70%. Regarding short-term risk, CATX is more volatile compared to CLPT. This indicates higher risk in terms of short-term price fluctuations for CATX.Check CLPT's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
CATX vs INFU Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, INFU has a market cap of 273.5M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while INFU trades at $13.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas INFU's P/E ratio is 33.49. In terms of profitability, CATX's ROE is -0.42%, compared to INFU's ROE of +0.16%. Regarding short-term risk, CATX is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for CATX.Check INFU's competition here
Profound Medical Corp. (NASDAQ: PROF)
CATX vs PROF Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, PROF has a market cap of 263.8M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while PROF trades at $7.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas PROF's P/E ratio is -7.37. In terms of profitability, CATX's ROE is -0.42%, compared to PROF's ROE of -0.28%. Regarding short-term risk, CATX is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for CATX.Check PROF's competition here
Quantum-Si incorporated (NASDAQ: QSI)
CATX vs QSI Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, QSI has a market cap of 263.6M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while QSI trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas QSI's P/E ratio is -2.88. In terms of profitability, CATX's ROE is -0.42%, compared to QSI's ROE of -0.45%. Regarding short-term risk, CATX is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for CATX.Check QSI's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
CATX vs TMCI Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, TMCI has a market cap of 262.7M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while TMCI trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas TMCI's P/E ratio is -4.30. In terms of profitability, CATX's ROE is -0.42%, compared to TMCI's ROE of -0.76%. Regarding short-term risk, CATX is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for CATX.Check TMCI's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
CATX vs MGRM Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas MGRM's P/E ratio is -12.00. In terms of profitability, CATX's ROE is -0.42%, compared to MGRM's ROE of -1.17%. Regarding short-term risk, CATX is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for CATX.Check MGRM's competition here
Nevro Corp. (NYSE: NVRO)
CATX vs NVRO Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas NVRO's P/E ratio is -1.91. In terms of profitability, CATX's ROE is -0.42%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, CATX is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for CATX.Check NVRO's competition here
Electromed, Inc. (AMEX: ELMD)
CATX vs ELMD Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, ELMD has a market cap of 223.4M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while ELMD trades at $27.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas ELMD's P/E ratio is 20.58. In terms of profitability, CATX's ROE is -0.42%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, CATX is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for CATX.Check ELMD's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
CATX vs TLSI Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, TLSI has a market cap of 199.5M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while TLSI trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas TLSI's P/E ratio is -1.93. In terms of profitability, CATX's ROE is -0.42%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, CATX is more volatile compared to TLSI. This indicates higher risk in terms of short-term price fluctuations for CATX.Check TLSI's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
CATX vs BSGM Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas BSGM's P/E ratio is -5.81. In terms of profitability, CATX's ROE is -0.42%, compared to BSGM's ROE of +6.96%. Regarding short-term risk, CATX is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for CATX.Check BSGM's competition here
RxSight, Inc. (NASDAQ: RXST)
CATX vs RXST Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, RXST has a market cap of 188.6M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while RXST trades at $4.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas RXST's P/E ratio is -4.01. In terms of profitability, CATX's ROE is -0.42%, compared to RXST's ROE of -0.20%. Regarding short-term risk, CATX is more volatile compared to RXST. This indicates higher risk in terms of short-term price fluctuations for CATX.Check RXST's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
CATX vs MDGS Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas MDGS's P/E ratio is -0.27. In terms of profitability, CATX's ROE is -0.42%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, CATX is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for CATX.Check MDGS's competition here
Neuronetics, Inc. (NASDAQ: STIM)
CATX vs STIM Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, STIM has a market cap of 163.4M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while STIM trades at $2.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas STIM's P/E ratio is -4.87. In terms of profitability, CATX's ROE is -0.42%, compared to STIM's ROE of -1.28%. Regarding short-term risk, CATX is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for CATX.Check STIM's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
CATX vs QIPT Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas QIPT's P/E ratio is -15.87. In terms of profitability, CATX's ROE is -0.42%, compared to QIPT's ROE of -0.08%. Regarding short-term risk, CATX is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for CATX.Check QIPT's competition here
Inogen, Inc. (NASDAQ: INGN)
CATX vs INGN Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, INGN has a market cap of 160M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while INGN trades at $6.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas INGN's P/E ratio is -6.63. In terms of profitability, CATX's ROE is -0.42%, compared to INGN's ROE of -0.20%. Regarding short-term risk, CATX is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for CATX.Check INGN's competition here
Quanterix Corporation (NASDAQ: QTRX)
CATX vs QTRX Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, QTRX has a market cap of 137.1M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while QTRX trades at $2.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas QTRX's P/E ratio is -1.14. In terms of profitability, CATX's ROE is -0.42%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, CATX is more volatile compared to QTRX. This indicates higher risk in terms of short-term price fluctuations for CATX.Check QTRX's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
CATX vs FOCL Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, FOCL has a market cap of 125.9M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while FOCL trades at $3.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas FOCL's P/E ratio is -3.25. In terms of profitability, CATX's ROE is -0.42%, compared to FOCL's ROE of -2.41%. Regarding short-term risk, CATX is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for CATX.Check FOCL's competition here
Owlet, Inc. (NYSE: OWLT)
CATX vs OWLT Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, OWLT has a market cap of 121.6M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while OWLT trades at $4.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas OWLT's P/E ratio is -29.71. In terms of profitability, CATX's ROE is -0.42%, compared to OWLT's ROE of -0.50%. Regarding short-term risk, CATX is more volatile compared to OWLT. This indicates higher risk in terms of short-term price fluctuations for CATX.Check OWLT's competition here
Pulmonx Corporation (NASDAQ: LUNG)
CATX vs LUNG Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, LUNG has a market cap of 109.9M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while LUNG trades at $2.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas LUNG's P/E ratio is -2.53. In terms of profitability, CATX's ROE is -0.42%, compared to LUNG's ROE of -0.98%. Regarding short-term risk, CATX is less volatile compared to LUNG. This indicates lower risk in terms of short-term price fluctuations for CATX.Check LUNG's competition here
iCAD, Inc. (NASDAQ: ICAD)
CATX vs ICAD Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas ICAD's P/E ratio is -20.37. In terms of profitability, CATX's ROE is -0.42%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, CATX is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for CATX.Check ICAD's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
CATX vs HJLI Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas HJLI's P/E ratio is N/A. In terms of profitability, CATX's ROE is -0.42%, compared to HJLI's ROE of -0.70%. Regarding short-term risk, CATX is more volatile compared to HJLI. This indicates higher risk in terms of short-term price fluctuations for CATX.Check HJLI's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
CATX vs ASXC Comparison November 2026
Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CATX stands at 95.9M. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, CATX is priced at $0.84 on the AMEX, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CATX currently has a P/E ratio of -0.63, whereas ASXC's P/E ratio is -1.12. In terms of profitability, CATX's ROE is -0.42%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, CATX is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for CATX.Check ASXC's competition here